Ozempic and Gastroparesis: What Texas Patients Should Know

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Legal Concerns

If you or a loved one has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis. Decades of pharmacovigilance have established that delayed gastric emptying can be a serious adverse effect of GLP-1 receptor agonists. This page reviews the clinical signals, diagnosis, and regulatory context for Ozempic-associated gastroparesis in Texas.

The Medical Link Between Ozempic and Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its pharmacological action includes slowing gastric emptying, a mechanism that contributes to glycemic control but also raises concerns about gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction—has emerged as a significant risk for some patients. This narrative examines the clinical presentation of gastroparesis, the pharmacological link to Ozempic, and the legal considerations for affected individuals in Texas, including the statute of limitations for filing claims. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The condition can severely impact quality of life, leading to malnutrition, dehydration, and hospitalizations. In the context of Ozempic use, the drug's known effect on gastric motility is a mechanistic pathway that can precipitate or exacerbate gastroparesis. Clinical trial data indicate that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo. In placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, compared to 32.7% for Ozempic 0.5 mg and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to these reactions was also higher: 3.1% for Ozempic 0.5 mg and 3.8% for Ozempic 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal reactions with frequencies below 5% include dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% Ozempic 0.5 mg, 1.5% Ozempic 1 mg), and gastritis (0.8% placebo, 0.8% Ozempic 0.5 mg, 0.4% Ozempic 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data underscore the drug's impact on the gastrointestinal tract.

Mechanistic Evidence and Risk Context

The mechanistic link between Ozempic and gastroparesis is rooted in its action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract, and their activation slows gastric emptying. While this effect is intended to reduce postprandial glucose excursions, it can become pathological in susceptible individuals, leading to symptomatic gastroparesis. Postmarketing reports have highlighted risks associated with delayed gastric emptying, including pulmonary aspiration during procedures requiring anesthesia or deep sedation. The FDA label notes rare postmarketing reports of pulmonary aspiration in patients on GLP-1 receptor agonists who had residual gastric contents despite preoperative fasting (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the clinical significance of gastroparesis as an adverse effect. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a critical issue. The prescribing information includes gastrointestinal adverse reactions but does not explicitly list gastroparesis as a warning or precaution. Patients may not be adequately informed about the potential for severe, persistent gastric symptoms that mimic or constitute gastroparesis. This gap in communication can delay diagnosis and treatment, worsening outcomes.

Legal Considerations for Texas Patients

For affected patients in Texas, legal considerations include the statute of limitations for filing a product liability claim. In Texas, the statute of limitations for personal injury claims, including those related to defective drugs, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. This timeline is crucial for patients who developed gastroparesis after using Ozempic. The clock may start when symptoms become severe enough to prompt medical evaluation and diagnosis. Given the gradual onset of gastroparesis symptoms, patients should seek legal counsel promptly to preserve their rights. Attorney-related considerations for affected patients involve documenting the timeline between Ozempic exposure and the onset of gastroparesis symptoms. Medical records should establish a temporal relationship, ideally with evidence of normal gastric function before starting Ozempic and subsequent diagnostic confirmation of gastroparesis. The statute of limitations in Texas requires careful attention to this timeline, as delays in filing can bar recovery. Patients should also consider whether the manufacturer provided adequate warnings about the risk of gastroparesis. If warnings were insufficient, a claim for failure to warn may be viable. The evidence from clinical trials and postmarketing reports supports the argument that Ozempic can cause significant gastrointestinal harm, yet the label does not specifically warn about gastroparesis. This omission may form the basis of a legal claim.

Summary and Next Steps

In summary, Ozempic use is associated with gastrointestinal adverse reactions, including dyspepsia, GERD, and gastritis, which can progress to or mimic gastroparesis. The drug's mechanism of slowing gastric emptying provides a plausible pathway for this harm. Patients in Texas who develop gastroparesis after using Ozempic should be aware of the two-year statute of limitations from the date of discovery of the injury. Legal counsel can help navigate the complexities of documenting the exposure timeline and assessing the adequacy of warnings. Prompt action is essential to protect legal rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Texas?

In Texas, the statute of limitations for personal injury claims, including those related to defective drugs like Ozempic, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For gastroparesis, this may be when symptoms become severe enough to prompt medical evaluation and diagnosis.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism to control blood sugar. In some individuals, this effect can become pathological, leading to symptomatic gastroparesis. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.